Clinical Trial Update: Different Doses of ZED1227 vs. Placebo in NAFLD [Phase 2]

View source ↗

Summary

Phase 2 trial comparing different doses of ZED1227 to placebo in non-alcoholic fatty liver disease with liver fibrosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• ZED1227

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: NAFLD, Liver Fibrosis | Phase 2 | Status: COMPLETED